crimson
01-14-2010, 07:05 PM
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRAŽ (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. ACTEMRA is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat RA, and may be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs (DMARDs).
More on this story here http://www.news-medical.net/news/20100108/Genentechs-ACTEMRA-approved-to-treat-RA.aspx
More on this story here http://www.news-medical.net/news/20100108/Genentechs-ACTEMRA-approved-to-treat-RA.aspx